JP2022519154A5 - - Google Patents

Info

Publication number
JP2022519154A5
JP2022519154A5 JP2021532325A JP2021532325A JP2022519154A5 JP 2022519154 A5 JP2022519154 A5 JP 2022519154A5 JP 2021532325 A JP2021532325 A JP 2021532325A JP 2021532325 A JP2021532325 A JP 2021532325A JP 2022519154 A5 JP2022519154 A5 JP 2022519154A5
Authority
JP
Japan
Prior art keywords
item
population
cells
items
immune cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021532325A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022519154A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2019/123684 external-priority patent/WO2020114491A1/en
Publication of JP2022519154A publication Critical patent/JP2022519154A/ja
Publication of JP2022519154A5 publication Critical patent/JP2022519154A5/ja
Priority to JP2024165533A priority Critical patent/JP2025000745A/ja
Pending legal-status Critical Current

Links

JP2021532325A 2018-12-07 2019-12-06 免疫療法のための組成物および方法 Pending JP2022519154A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024165533A JP2025000745A (ja) 2018-12-07 2024-09-24 免疫療法のための組成物および方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN201811501797 2018-12-07
CN201811501797.8 2018-12-07
CNPCT/CN2019/073252 2019-01-25
CN2019073252 2019-01-25
CN201910297171.8 2019-04-12
CN201910297171 2019-04-12
CN2019097996 2019-07-26
CNPCT/CN2019/097996 2019-07-26
PCT/CN2019/123684 WO2020114491A1 (en) 2018-12-07 2019-12-06 Compositions and methods for immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024165533A Division JP2025000745A (ja) 2018-12-07 2024-09-24 免疫療法のための組成物および方法

Publications (2)

Publication Number Publication Date
JP2022519154A JP2022519154A (ja) 2022-03-22
JP2022519154A5 true JP2022519154A5 (https=) 2022-12-14

Family

ID=70974083

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021532325A Pending JP2022519154A (ja) 2018-12-07 2019-12-06 免疫療法のための組成物および方法
JP2024165533A Pending JP2025000745A (ja) 2018-12-07 2024-09-24 免疫療法のための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024165533A Pending JP2025000745A (ja) 2018-12-07 2024-09-24 免疫療法のための組成物および方法

Country Status (10)

Country Link
US (2) US20210369779A1 (https=)
EP (1) EP3891272A4 (https=)
JP (2) JP2022519154A (https=)
KR (1) KR20210125986A (https=)
CN (2) CN113574172A (https=)
AU (1) AU2019393243A1 (https=)
IL (1) IL283644A (https=)
SG (1) SG11202106053SA (https=)
TW (1) TW202100747A (https=)
WO (1) WO2020114491A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
AU2019372673A1 (en) 2018-11-01 2021-05-27 Gracell Biotechnologies (Shanghai) Co., Ltd. Compositions and methods for T cell engineering
BR112022011795A2 (pt) 2019-12-20 2022-08-30 Instil Bio Uk Ltd Métodos para preparar e isolar uma população terapêutica de linfócitos e para tratar câncer em um indivíduo, população terapêutica de linfócitos, bolsa criopreservada, recipiente flexível, e, sistema para extração de linfócitos
EP4262828A1 (en) * 2020-12-18 2023-10-25 Instil Bio (Uk) Limited Tumor infiltrating lymphocytes and anti-cd47 therapeutics
CN117594124A (zh) * 2021-06-15 2024-02-23 南京医科大学 一种基于单核细胞预测胶质瘤的试剂盒、系统和应用
WO2023278553A1 (en) * 2021-07-01 2023-01-05 Kite Pharma, Inc. Closed-system and method for autologous and allogeneic cell therapy manufacturing
TWI837927B (zh) * 2022-11-03 2024-04-01 沛爾生技醫藥股份有限公司 生產富含幹細胞樣記憶ｔ細胞之人類嵌合抗原受體ｔ細胞的方法
CN116789107A (zh) * 2023-06-15 2023-09-22 江南大学 一种NSP-CDs/Ag+荧光纳米探针及其在检测α-脂霉素中的应用
CN117924518B (zh) * 2024-01-05 2025-08-22 苏州艾凯利元生物科技有限公司 用于nk细胞的嵌合抗原受体及工程化的nk细胞
CN118891290A (zh) * 2024-04-12 2024-11-01 科济生物医药（上海）有限公司 细胞免疫疗法的组合物和方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070036773A1 (en) * 2005-08-09 2007-02-15 City Of Hope Generation and application of universal T cells for B-ALL
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2012151266A1 (en) * 2011-05-03 2012-11-08 Michael Har-Noy Methods for handling biological drugs containing living cells
WO2014055442A2 (en) * 2012-10-01 2014-04-10 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
AU2013204922B2 (en) * 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
US20160017286A1 (en) * 2013-03-06 2016-01-21 The Trustees Of The University Of Pennsylvania Ikaros inhibition to augment adoptive t cell transfer
AU2015214145A1 (en) * 2014-02-04 2016-08-25 Kite Pharma. Inc. Methods for producing autologous T cells useful to treat B cell malignancies and other cancers and compositions thereof
ES2987570T3 (es) * 2014-11-05 2024-11-15 Juno Therapeutics Inc Métodos para la transducción y el procesamiento de células
WO2017070042A1 (en) * 2015-10-20 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing t cell populations using akt inhibitors
CN108017717B (zh) * 2018-01-24 2019-08-16 首都医科大学宣武医院 一种用于体外高效定向扩增的嵌合抗原受体及其应用
US20210301255A1 (en) * 2018-09-10 2021-09-30 Atara Biotherapeutics, Inc. Methods for expanding antigen-specific car-t cells, compositions and uses related thereto
CN110358734B (zh) * 2019-06-13 2020-08-25 首都医科大学宣武医院 以Tcm为主要效应成分的CAR-T制备方法及其应用

Similar Documents

Publication Publication Date Title
JP2022519154A5 (https=)
Vivier et al. Natural killer cell therapies
Manier et al. Current state and next-generation CAR-T cells in multiple myeloma
Gargett et al. Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2
Daher et al. CAR‐NK cells: the next wave of cellular therapy for cancer
JP6563554B2 (ja) Ｃａｒの抗腫瘍活性のための毒性管理
Priceman et al. Smart CARs engineered for cancer immunotherapy
Jensen et al. Designing chimeric antigen receptors to effectively and safely target tumors
US10918667B2 (en) Modified cell expressing therapeutic agent and uses thereof
Cappuzzello et al. Cytokines for the induction of antitumor effectors: The paradigm of Cytokine-Induced Killer (CIK) cells
JP2021058196A5 (https=)
Kwon et al. Molecular checkpoints controlling natural killer cell activation and their modulation for cancer immunotherapy
Mata-Molanes et al. Cancer immunotherapy with cytokine-induced killer cells
JP2017522893A (ja) Ｒｏｒ１特異的多重鎖キメラ抗原受容体
AU2016349724A1 (en) Chimeric receptors containing TRAF-inducing domains and related compositions and methods
JP2021505615A5 (https=)
CN117802051A (zh) 修饰的细胞及组合物
Sukari et al. Unleash the power of the mighty T cells-basis of adoptive cellular therapy
CN110257338B (zh) 嵌合细胞因子受体
Kiaei et al. Advances in natural killer cell therapies for breast cancer
KR20220144888A (ko) 최적화된 다기능 t 세포를 포함하는 키메라 수용체 t 세포를 사용하는 치료
Marple et al. Improving CAR T-cells: The next generation
US20230227576A1 (en) Receptors providing targeted costimulation for adoptive cell therapy
KR20220012224A (ko) 입양 전달 요법에서 t 림프구 및 nk 세포의 확장 및 분화를 위한 방법
Hu et al. Application of adoptive cell therapy in malignant melanoma